Henry Schein (NASDAQ:HSIC) Given Neutral Rating at Robert W. Baird

Robert W. Baird reaffirmed their neutral rating on shares of Henry Schein (NASDAQ:HSIC) in a research report sent to investors on Monday morning, Marketbeat Ratings reports. Robert W. Baird currently has a $72.00 price objective on the stock, down from their prior price objective of $82.00.

Other equities analysts also recently issued reports about the stock. Piper Sandler dropped their price objective on shares of Henry Schein from $83.00 to $77.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 30th. Barrington Research dropped their price objective on shares of Henry Schein from $90.00 to $86.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 6th. Evercore ISI increased their price objective on shares of Henry Schein from $72.00 to $78.00 and gave the company an “in-line” rating in a research note on Wednesday, July 9th. Wells Fargo & Company dropped their price objective on shares of Henry Schein from $80.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 6th. Finally, Wall Street Zen downgraded shares of Henry Schein from a “buy” rating to a “hold” rating in a research note on Thursday, April 17th. Seven investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $78.36.

Henry Schein Stock Performance

Shares of NASDAQ:HSIC opened at $70.68 on Monday. The firm has a market cap of $8.60 billion, a PE ratio of 22.09, a price-to-earnings-growth ratio of 2.37 and a beta of 0.87. The firm’s 50 day simple moving average is $71.56 and its 200-day simple moving average is $71.33. Henry Schein has a one year low of $60.56 and a one year high of $82.49. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.75 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Monday, May 5th. The company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. The business had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.24 billion. Henry Schein had a net margin of 3.21% and a return on equity of 14.87%. The company’s quarterly revenue was down .1% compared to the same quarter last year. During the same period last year, the company posted $1.10 earnings per share. As a group, equities analysts predict that Henry Schein will post 4.74 EPS for the current year.

Institutional Investors Weigh In On Henry Schein

Several institutional investors have recently bought and sold shares of the company. Investment Management Corp VA ADV purchased a new position in shares of Henry Schein in the fourth quarter worth $32,000. Rakuten Securities Inc. purchased a new position in shares of Henry Schein in the first quarter worth $34,000. CX Institutional raised its holdings in shares of Henry Schein by 107.3% in the second quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after buying an additional 337 shares during the last quarter. Whittier Trust Co. raised its holdings in shares of Henry Schein by 714.3% in the first quarter. Whittier Trust Co. now owns 798 shares of the company’s stock worth $55,000 after buying an additional 700 shares during the last quarter. Finally, Quarry LP purchased a new position in shares of Henry Schein in the first quarter worth $71,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.